Dice Question Streamline Icon: https://streamlinehq.com

Therapeutic efficacy of post-exposure passive immunization against CHIKV

Ascertain whether passive immunization using hyperimmune serum or monoclonal antibodies can effectively treat Chikungunya virus disease after infection has already begun.

Information Square Streamline Icon: https://streamlinehq.com

Background

Monoclonal antibodies targeting CHIKV E1/E2 have shown protective effects in animal models, particularly in prophylactic contexts. However, their utility as treatment once infection is established is not established.

Clarifying post-exposure efficacy would guide therapeutic development and clinical deployment in acute CHIKV cases.

References

It is uncertain, nevertheless, if hyper immune serum or monoclonal antibodies may be used to passively immunize against CHIKV illness once infection has already begun [142].

— Chikungunya: The Silent Threat in the Shadows (2411.12779 - Talib et al., 19 Nov 2024) in Section 11. Treatment